Solvay Reports Third-Quarter Profits Down; Evaluates Options for Reinvestment of Pharma Proceeds

Solvay reported a 2% decrease in third quarter recurring earnings before interest and taxes (Rebit) at €285 million ($424 million) on 10% lower sales of €2.24 billion, citing difficult market conditions. Earnings before interest and tax (Ebit) fell 32% to €255 million. Of Solvay's three business segments, chemicals, plastics and pharmaceuticals, only the pharma unit showed an increase in sales and Rebit. Solvay is selling the pharma business. Chemicals' Rebit was down 21% at €56 million on 18% lower sales of €658...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers